Abbreviations:
ICH
ALLERGIC RHINITIS
adverse eventsallergic rhinitisconfidence intervaldialyzable leukocyte extractminimal important differencequality of lifeRhinoconjunctivitis Quality of Life QuestionnaireThis work was supported by the Instituto Politécnico Nacional, a public university and producer of the Dialyzable Leukocyte Extract used in this study. Their role was to supply medication without any role in the study design, protocol preparation, data collection, data analysis, interpretation of data, manuscript preparation, or the decision to submit the manuscript for publication.This research was designed, approved, and conducted ethically in accordance with the World Medical Association Declaration of Helsinki and the principles of Good Clinical Practice by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Written informed consent was obtained from all the trial participants before all trial-related procedures were initiated. The study protocol was approved by an independent Ethics Committee (IC 13-001).SMP-T was involved in the development of Transferon OralAll data generated or analyzed during this study are included in this published article [and its supplementary information files].Supplemental Digital Content is available for this article.How to cite this article: Homberg TA, Lara I, Andaluz C, Cervantes-Trujano E, Hernández-Martínez PM, Pérez-Tapia SM, Jiménez-Martínez MC. Quality of life in adult patients using dialyzable leukocyte extract for allergic rhinitis. Medicine 2023;102:27(e34186).